P&G Wins Patent Infringement Lawsuit Against Teva Pharma For Osteoporosis Therapy Actonel - Quick Facts

Thu. February 28, 2008; Posted: 04:53 PM

(RTTNews) - Procter & Gamble Co. (PG | news | PowerRating | PR Charts ) said that the United States District Court of Delaware ruled in favor of the company in the patent infringement lawsuit filed against Teva Pharmaceuticals USA Inc. (TEVA | news | PowerRating | PR Charts ). The positive ruling protects P&G's rights in the U.S. to exclusively market the osteoporosis therapy Actonel or risedronate sodium tablets.

Today's Court ruling upheld the P&G patent, expressly rejecting Teva's validity challenge.

Actonel is the only oral osteoporosis therapy proven to reduce the risk of vertebral fractures in just one year. The Actonel patent life extends through the end of 2013, excluding any potential extensions.

For full details on Procter & Gamble Co (PG) click here. Procter & Gamble Co (PG) has Short Term PowerRatings of 6. Details on Procter & Gamble Co (PG) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.